Compare Enphase Energy Inc (ENPH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Organon & Co. Common Stock — how do they compare? Enphase Energy Inc trades at $29.02 (market cap $4.23B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Enphase Energy Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Organon & Co. Common Stock for 0 Days on average.
| ENPH | OGN | |
|---|---|---|
Market Cap | $4.23B | $3.62B |
Volume | 4,755,897 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $72.33 | $13.81 |
52-Week Low | $26.12 | $5.70 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $3.88B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $29.35, down 6.8% in the last session, reflecting recent volatility amid broader solar sector pressures. The stock shows a bearish technical signal with key support at $29. Valuation ratios like a P/E of 31.71 and P/S of 3.22 suggest a premium, while recent quarters saw mixed earnings with two misses. Positive developments include utility approvals for its IQ Meter Collar and advancements in solid-state transformer technology for AI data centers.
The outlook is cautious; while analyst consensus targets $43.18 implying upside, high borrowing costs and competitive risks weigh on solar stocks. Revenue declined from 2023's $2.3B to $1.47B in 2025, though net margins improved. Investors should balance growth potential in energy tech against execution risks and market sentiment shifts.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
